Long-Term CARTITUDE 4: Rate of MRD Negativity

Panelists discuss how data from the long-term CARTITUDE-4 update reveal a notable rate of minimal residual disease (MRD) negativity with ciltacabtagene autoleucel, emphasizing its potential to enhance long-term outcomes in patients with lenalidomide-refractory multiple myeloma.

EP: 1.Impact of CAR T-Cell Therapy in R/R MM

EP: 2.Overview of CARTITUDE-4: Study Design, Baseline Characteristics, and Efficacy

EP: 3.Long-Term CARTITUDE-4 Study Update in MM

EP: 4.Long-Term CARTITUDE-4 Update: ORR and DOR

Now Viewing

EP: 5.Long-Term CARTITUDE 4: Rate of MRD Negativity

EP: 6.Safety Data from the Long-Term CARTITUDE-4 Update

EP: 7.Looking Ahead and Key Takeaways

Recent Videos